Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 6/20 | 0.39 |
| ▸ | NOS1 | P29475 | 6/20 | 0.39 |
| ▸ | NOS2 | P35228 | 6/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15537284 | 1.00 | NCF1 (0.44) | NCF1LMNAPLGPLATCYP2C9 | |
| SCHEMBL17268183 | 1.00 | NCF1 (0.44) | NCF1LMNAPLGPLATCYP2C9 | |
| Hydrochloric Acid SCHEMBL17260637 | 0.97 | NCF1 (0.42) | NCF1LMNAPLGPLATCYP2C9 | |
| Ethylamine SCHEMBL7195532 | 0.88 | — | — | |
| Propylamine SCHEMBL29170833 | 0.86 | CYP2C9 (0.40) | LMNACYP2C9NOS3NOS1NOS2 | |
| Methylamine SCHEMBL7186567 | 0.85 | — | — | |
| SCHEMBL129995 | 0.85 | — | — | |
| SCHEMBL5691374 | 0.85 | CYP1A2 (0.48) | LMNACYP2C9NOS3NOS1NOS2 | |
| SCHEMBL17592348 | 0.84 | CYP1A2 (0.58) | NCF1LMNAPLGPLATNOS3 | |
| SCHEMBL17592419 | 0.84 | CYP1A2 (0.58) | NCF1LMNAPLGPLATNOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210236474-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AS LSD-1 INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236474-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AS LSD-1 INHIBITORS | KDM1A, KDM4A, KDM1B | NCF1 2944/4885LMNA 1804/4885PLG 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.